Most Read News

The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.

The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.

Out of the ₹752 crore investment, ₹603 crore will be utilized upfront to reduce debt across Samhi’s portfolio and cover transaction-related expenses.

On a quarter-on-quarter basis, the EBITDA grew sharply by 40.02% over ₹116.7 crore seen in Q3FY25.

UltraTech Cement, Bajaj FinServ, Bajaj Finance are the stocks that hits 52-week high in Sensex and Nifty

The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.

Net profit grew 10% sequentially from the last quarter (Q3 FY25) as well, reflecting growth momentum.

Though there was a fall in quarterly losses, TTML's operating revenue fell by 5%, coming down to ₹308.27 crore in Q4 FY25 from ₹323.29 crore in Q4 FY24.

The NFO is available for subscription from April 23 to May 07, 2025.

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.